Midwest Professional Planners LTD. purchased a new position in shares of BioNTech SE (NASDAQ:BNTX) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 1,377 shares of the company’s stock, valued at approximately $308,000.
Several other hedge funds have also recently bought and sold shares of BNTX. Baillie Gifford & Co. bought a new position in shares of BioNTech during the 1st quarter worth $735,723,000. Price T Rowe Associates Inc. MD grew its stake in shares of BioNTech by 31.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,074,906 shares of the company’s stock worth $226,559,000 after acquiring an additional 500,085 shares during the period. Coatue Management LLC bought a new position in BioNTech in the 1st quarter worth about $37,326,000. Mitsubishi UFJ Trust & Banking Corp bought a new position in BioNTech in the 1st quarter worth about $30,171,000. Finally, Polar Capital Holdings Plc bought a new position in BioNTech in the 1st quarter worth about $24,568,000. Institutional investors own 14.49% of the company’s stock.
BioNTech stock traded up $10.50 during mid-day trading on Wednesday, reaching $345.38. 14,308 shares of the stock traded hands, compared to its average volume of 3,083,459. The stock has a market capitalization of $83.76 billion, a PE ratio of 17.52 and a beta of -1.59. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.67 and a quick ratio of 2.57. BioNTech SE has a 12-month low of $58.81 and a 12-month high of $464.00. The business’s 50-day moving average is $321.74 and its 200-day moving average is $221.83.
Several research analysts have commented on BNTX shares. Wolfe Research started coverage on BioNTech in a research note on Monday, July 19th. They issued an “outperform” rating and a $248.00 target price for the company. Bryan, Garnier & Co upgraded BioNTech from a “neutral” rating to a “buy” rating in a research note on Wednesday, August 11th. SVB Leerink raised their target price on BioNTech from $159.00 to $293.00 and gave the stock a “market perform” rating in a research note on Friday, August 13th. Redburn Partners restated a “sell” rating and issued a $146.00 target price on shares of BioNTech in a research note on Wednesday, June 16th. They noted that the move was a valuation call. Finally, The Goldman Sachs Group downgraded BioNTech from a “buy” rating to a “neutral” rating in a research report on Sunday, August 8th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $200.62.
BioNTech Company Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors.
See Also: Trade War
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.